Biotech / Finance

Novartis’ heart failure drug Entresto improves glycemic control in Phase III study

From PBR - News
March 20, 2017 - 5:08am
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.

Continue reading this article »